While GRP78 expression (i.e., existence of GRP78(+) cells) correlated with favorable prognosis in lung cancer [42], and increased 5-year survival in colon cancer [43], in some cases, conflicting results with negative clinical outcomes [44, 45] were observed in breast cancer [46], gastric cancer [47], pancreatic cancer [48] and liver cancer [49]. This evidence concerns the gene HSPA5 and liver cancer.